Reuters logo
BRIEF-Bristol-Myers Squibb says ‍two opdivo trials show 3-year survival benefit
September 8, 2017 / 10:16 AM / 3 months ago

BRIEF-Bristol-Myers Squibb says ‍two opdivo trials show 3-year survival benefit

Sept 8 (Reuters) - Bristol-Myers Squibb Co:

* Bristol-Myers Squibb - ‍two pivotal opdivo trials show 3-year survival benefit in patients with previously treated advanced non-small cell lung cancer​

* Bristol-Myers Squibb Co - ‍results represent longest phase 3 follow-up data reported for a PD-1 inhibitor in second-line non-small cell lung cancer​

* Bristol-Myers Squibb-‍data continued to show benefit with opdivo in overall population, with nearly triple, double patients alive at 3 years versus docetaxel​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below